Insomnia News and Research

Latest Insomnia News and Research

Post-operative complications after oesophageal cancer surgery may cause other health problems

Oesophageal cancer is a very serious form of cancer that, if not fatal, requires extensive surgery. A new study from Karolinska Institutet in Sweden shows that when serious complications arise after surgery for oesophageal cancer, many patients suffer other health problems, such as breathlessness, fatigue, insomnia and eating problems, for five years afterwards.

4 Apr 2012

UCB receives FDA approval for Neupro to treat idiopathic Parkinson's, RLS

UCB announced today that the U.S. Food and Drug Administration (FDA) approved Neupro (Rotigotine Transdermal System) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson's disease (PD) and as a treatment for moderate-to-severe primary Restless Legs Syndrome.

3 Apr 2012

Regular walking regimen can benefit cancer survivors

Researchers have affirmed that pancreatic cancer patients can literally take a step-by-step approach to combat fatigue. A study published in the April issue of the Journal of the American College of Surgeons reports that patients who underwent an operation as part of their cancer treatment and then started a regular walking regimen experienced less fatigue than cancer survivors who did not do the walking program.

2 Apr 2012

Sleep enhances emotionally positive memories

Sleep plays a powerful role in preserving our memories. But while recent research shows that wakefulness may cloud memories of negative or traumatic events, a new study has found that wakefulness also degrades positive memories. Sleep, it seems, protects positive memories just as it does negative ones, and that has important implications for the treatment of post-traumatic stress disorder.

2 Apr 2012

Depression more prevalent among stroke and transient ischemic attack survivors

Depression is more prevalent among stroke and transient ischemic attack survivors than in the general population, researchers reported in the American Heart Association's journal Stroke.

29 Mar 2012

Roaring snores could be sounds of obstructive sleep apnea

Roaring snores that rumble a room or violent snorts for breath during sleep could be sounds of obstructive sleep apnea. While a true diagnosis is only possible with a sleep study, if left untreated, the sleep disorder could be fatal.

28 Mar 2012

Teva, IVAX receive FDA approval for generic Lexapro to treat depression and GAD

The U.S. Food and Drug Administration today approved the first generic Lexapro (escitalopram tablets) to treat both depression and generalized anxiety disorder in adults.

27 Mar 2012

Rifaximin and lubiprostone offer best options for patients with IBS

Cedars-Sinai researchers have determined that two prevalent drug therapies - rifaximin and lubiprostone - offer some of the best options for treating irritable bowel syndrome, a widespread disorder that affects up to one in five Americans.

26 Mar 2012

Heptares exercises exclusive option to license new A2A antagonist for CNS disorders

Heptares Therapeutics, the leading GPCR drug discovery company, announces that an operating company of Shire PLC, the global specialty biopharmaceutical company, has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares that is currently in preclinical development.

20 Mar 2012

Obesity appears to increase risk of mortality tied to sleeping pills

Obesity appears to significantly increase the risk of death tied to sleeping pills, nearly doubling the rate of mortality even among those prescribed 18 or fewer pills in a year, researchers reported Friday.

17 Mar 2012

Teva gets exclusive 180 days to market generic antidepressant and anti-anxiety pill Lexapro

Teva Pharmaceutical Industries Ltd. Has won U.S. approval to sell the first generic version of Lexapro for depression and anxiety. Teva has been granted a 180-day exclusivity, so no other firm can market the generic medication in the United States in that timeframe, the Food and Drug Administration (FDA) said in a news release.

15 Mar 2012

Shire to commence two Vyvanse and Concerta Phase 4 comparison trials for ADHD

As part of its continued commitment to ADHD research, Shire plc, the global specialty biopharmaceutical company, today announced it is initiating two Phase 4 clinical trials to compare Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) to Concerta (methylphenidate HCl) Extended-Release Tablets.

7 Mar 2012

Sleep specialists offer advice on why Daylight Saving Time can be hazardous to health

It's National Sleep Awareness Week, and Loyola University Health System sleep specialists are offering advice on -- Why Daylight Saving Time, which begins Sunday, March 11, can be hazardous to your health.

6 Mar 2012

Good sleep routine tips from people who sleep well

The survey showed that the events of the evening have an impact on the night ahead. Surveyors found that a good sleeper ensure they have at least two hours and seven minutes 'down time' before hitting the bed. The average person will watch at least an hour and three quarters of television, opting for soap operas or comedy quiz shows. And when going to bed, Brits have another 20 minutes rest time before finally falling asleep at 10:26pm.

4 Mar 2012

Sleep improves with age dispelling age old myth

A new study dispels the age old belief that sleep doesn’t get more difficult with age. The study shows that sleep quality tends to improve the older people got, with adults in their 80s getting better sleep than any other age group surveyed. The new study was published in the journal Sleep.

2 Mar 2012

NEJM publishes results from two Jakafi Phase III studies on MF

The New England Journal of Medicine (NEJM) today published results from two Phase III studies (COMFORT-I and COMFORT-II) of Jakafi (ruxolitinib), a JAK1 and JAK2 inhibitor recently approved by the Food and Drug Administration (FDA) for the treatment of intermediate or high-risk myelofibrosis.

1 Mar 2012

Sleeping pills may raise risk of death: Study

According to a U.S. study, people who take certain prescription sleeping pills even once in a while may be up to five times more susceptible to early death. In the U.S., an estimated six per cent to 10 per cent of adults used the drugs in 2010.

29 Feb 2012

Gedeon Richter and Forest Labs' cariprazine Phase III trials on schizophrenia meet primary endpoint

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced positive top-line results in 2 Phase III clinical trials of cariprazine (RGH-188) for the treatment of acute exacerbation of schizophrenia.

28 Feb 2012

Sleeping pills may increase risk of cancer-related death

People are relying on sleeping pills more than ever to get a good night's rest, but a new study by Scripps Clinic researchers links the medications to a 4.6 times higher risk of death and a significant increase in cancer cases among regular pill users.

28 Feb 2012

The Lancet publishes Takeda's TAK-875 Phase 2 data on type 2 diabetes

Phase 2 clinical data of an investigational type 2 diabetes therapy, TAK-875 of Takeda Pharmaceutical Company Limited, were published online first in The Lancet.

27 Feb 2012